News

Study Reveals How Pancreatic Cancer Triggers Severe Muscle Loss

Research Advances /

Researchers used single-nucleus RNA sequencing to study pancreatic ductal adenocarcinoma (PDAC) cachexia, revealing how tumors systematically break down skeletal muscle. Using a KPC mouse model, they discovered a unique “cachectic cluster” of muscle nuclei that activates protein-degrading genes while suppressing structural genes. Not all muscle fibers were equally affected—fast-glycolytic Type IIb fibers suffered the most, […]

Study Reveals How Pancreatic Cancer Triggers Severe Muscle Loss Read More »

Nivolumab Rechallenge Fails to Improve Outcomes in ccRCC, Study Finds

Targeted Therapy /

The Phase 3 TiNivo-2 study tested whether adding nivolumab to tivozanib improves outcomes for patients with metastatic clear cell renal cell carcinoma (ccRCC) who progressed on prior immune checkpoint inhibitors (ICIs). The trial found that combining nivolumab with tivozanib did not improve progression-free survival compared to tivozanib alone. However, tivozanib monotherapy remained highly effective in the

Nivolumab Rechallenge Fails to Improve Outcomes in ccRCC, Study Finds Read More »

Gilteritinib Maintenance Therapy Improves Survival After Stem Cell Transplant in AML

Targeted Therapy /

A systematic review shows that using gilteritinib as maintenance therapy after stem cell transplant (HSCT) can significantly improve survival for patients with high-risk, relapsed or refractory FLT3-mutated acute myeloid leukemia (AML). Across eight studies with 134 patients, one-year overall survival ranged from 72% to 100%, and two-year survival remained strong at 56% to 60%. Gilteritinib

Gilteritinib Maintenance Therapy Improves Survival After Stem Cell Transplant in AML Read More »

MaaT013 Boosts Survival in Severe Gut GVHD Patients

Immunotherapy /

Final results from the Phase 3 ARES trial, presented at the EBMT 52nd Annual Meeting, show that the fecal microbiotherapy MaaT013 significantly improves survival for patients with life-threatening, drug-resistant gut graft-versus-host disease (aGVHD). Patients with gastrointestinal aGVHD who fail steroids and ruxolitinib usually face a median survival of about 86 days. In the trial, MaaT013—a

MaaT013 Boosts Survival in Severe Gut GVHD Patients Read More »

Tebentafusp Linked to Common Skin Side Effects in Melanoma Study

Immunotherapy /

A retrospective study shows that skin-related side effects are very common in patients treated with tebentafusp for metastatic uveal melanoma, with important findings in non-White patients. About 76.5% of patients developed a rash, often after the first infusion. Other common symptoms included itching, swelling, and dry skin. The study also found differences by race, with

Tebentafusp Linked to Common Skin Side Effects in Melanoma Study Read More »

New CAR T Therapy YTB323 Shows Strong Results in Advanced Leukemia

Targeted Therapy /

Data from a phase 1/2 study presented at the EBMT 52nd Annual Meeting shows that rapcabtagene autoleucel (YTB323), a next-generation CAR T-cell therapy, is highly effective for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). After a median follow-up of 27.7 months, 86% of patients responded to treatment within three months. All responders

New CAR T Therapy YTB323 Shows Strong Results in Advanced Leukemia Read More »

pembrolizumab Shows Lasting Benefit in Preventing Melanoma Recurrence

Immunotherapy /

A secondary analysis of the Phase 3 KEYNOTE-716 trial, published in JAMA Network, shows that adjuvant pembrolizumab continues to provide strong benefits for patients with resected stage IIB or IIC melanoma. The treatment significantly improved recurrence-free survival, with a 48-month rate of 68.7% compared to 56.5% for placebo. The study also found that immunotherapy did

pembrolizumab Shows Lasting Benefit in Preventing Melanoma Recurrence Read More »

Home-Based Chemotherapy Program Shows Safe Results in Early Study

Treatment /

A study shows that chemotherapy can be safely and effectively given at home through its “Cancer CARE Beyond Walls” program. In this pilot program, a multidisciplinary team delivered 93 intravenous infusions to 10 patients in their homes. The results showed no treatment-related reactions or catheter infections, suggesting the approach is both safe and feasible. The

Home-Based Chemotherapy Program Shows Safe Results in Early Study Read More »

New Four-Marker Blood Test Boosts Early Detection of Pancreatic Cancer

Research Advances /

Researchers have developed a new blood test that could greatly improve early detection of pancreatic ductal adenocarcinoma, one of the most aggressive cancers. Traditional markers such as CA19-9 and THBS2 often lack accuracy when used alone, limiting their usefulness in screening. The new approach combines four proteins—CA19-9, THBS2, and two newly identified markers, ANPEP and

New Four-Marker Blood Test Boosts Early Detection of Pancreatic Cancer Read More »

Immunotherapy’s Hidden Burden: Long-Term immune-related adverse effects Emerge as Growing Challenge

Immunotherapy /

A growing issue in cancer care is the long-term side effects from immunotherapy. These immune-related adverse effects can appear more than a year after treatment begins or last for years because immunotherapy reshapes the immune system. These delayed effects are hard to recognize, as they can resemble aging, other illnesses, or cancer itself. Patients often

Immunotherapy’s Hidden Burden: Long-Term immune-related adverse effects Emerge as Growing Challenge Read More »